You are here

Article Text

Article menu
Download PDFPDF
Letter
Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency

https://doi.org/10.1136/annrheumdis-2018-214037

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • CB and MLF contributed equally.

    • Handling editor Josef S Smolen

    • Contributors CB, DB, AC and BN collected clinical data. MLF, GIR, VB, DD and LC performed the experiments and analysed the data. CB and MLF wrote the paper. SB, YJC and BN supervised the study. All authors have read the final approval of the version published.

    • Funding MLF is supported by the Institut National de la Santé et de la Recherche Médicale (grant number 000427993). YJC acknowledges the European Research Council (GA 309449), and a state subsidy managed by the National Research Agency (France) under the 'Investments for the Future' programme bearing the reference ANR-10-IAHU-01. YJC and DD acknowledge the ANR (grant CE17001002).

    • Competing interests None declared.

    • Patient consent Parental/guardian obtained.

    • Ethics approval The study was approved by the Comité de Protection des Personnes (ID-RCB/EUDRACT: 2014-A01017-40).

    • Provenance and peer review Not commissioned; externally peer reviewed.